Acute Coronary Syndromes (ACS)NCT07276256
Association Between SYNTAX Score and Leukoglycemic Index In Patients Wiht Acute Coronary Syndrome
An observational study of Acute Coronary Syndromes (ACS), run by Kırıkkale University at 1 site in Turkey (Türkiye).
Trial summary
This study looks at people who come to the hospital with acute coronary syndrome, a serious heart condition. When these patients first arrive, doctors take routine blood tests. The investigators use these test results to calculate a value called the leukoglycemic index (LGI), which combines white blood cell count and… Read more about this study
- Who is it for?
- Ages 18 to 88 years
- Conditions the study is for
- Acute Coronary Syndromes (ACS)
- What is being tested?
- leukoglycemic index calculation
- How many people
- 552 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 24 Sep 2025to 21 Oct 2025
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 88 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with acute coronary syndrome
Who may be able to join
- Adult patients aged 18 years and older
- Patients who underwent coronary angiography due to acute coronary syndrome
Who cannot join
- Patients with diabetes mellitus (Diagnosis based on current use of oral antidiabetic or insulin therapy and/or fasting glucose level ≥126 mg/dL and HbA1c ≥6.5%)
- Patients with atrial fibrillation, history of pacemaker implantation, asthma, pulmonary hypertension, pregnancy, anemia, malignancy, rheumatoid arthritis, or peripheral artery disease
- Obese individuals (defined as body mass index [BMI] >30 kg/m²)
- Patients whose medical records could not be accessed
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Kırıkkale university
Kirikkale, Kırıkkale, 71000
About this study
This study looks at people who come to the hospital with acute coronary syndrome, a serious heart condition. When these patients first arrive, doctors take routine blood tests. The investigators use these test results to calculate a value called the leukoglycemic index (LGI), which combines white blood cell count and blood sugar level. The investigators also use a heart imaging score called the SYNTAX score to see how complex their coronary artery disease is.
Patients are divided into two groups based on their SYNTAX scores: one group with lower scores (22 or less), and one with higher scores (above 22). The investigators compare their health data to see if LGI is linked to the severity of their heart disease. The investigators also check if LGI can help predict how complex the disease is. Information like age, family history, and chronic illnesses is collected from patient records and medical interviews.
Read the detailed description
This observational study aims to evaluate the association between the SYNTAX score-a validated angiographic tool used to assess the complexity of coronary artery disease-and the leukoglycemic index (LGI), a composite biomarker calculated from white blood cell count and blood glucose level. The study population consists of patients diagnosed with acute coronary syndrome (ACS) who were admitted to the hospital and underwent coronary angiography as part of their clinical evaluation.
At the time of initial hospital admission, routine laboratory parameters were obtained, including complete blood count and fasting glucose levels. These values were used to calculate the LGI. Patients were stratified into two groups based on their SYNTAX scores: Group I (SYNTAX score ≤22) and Group II (SYNTAX score >22). Demographic characteristics, family history of cardiovascular disease, and chronic comorbidities (such as diabetes mellitus, hypertension, and hyperlipidemia) were extracted from patient medical records and clinical anamnesis.
The primary objective of the study is to determine whether LGI correlates with the angiographic severity of coronary artery disease as measured by the SYNTAX score. Secondary objectives include identifying independent predictors of coronary complexity and evaluating the potential role of LGI as a non-invasive biomarker in risk stratification.
Statistical analyses will be performed using SPSS software. Normality of data distribution will be assessed using the Shapiro-Wilk test. Depending on distribution characteristics, appropriate parametric (e.g., Student's t-test) or non-parametric (e.g., Mann-Whitney U test) methods will be applied for group comparisons. Pearson correlation analysis will be used to assess the relationship between LGI and SYNTAX score. Multivariate linear and logistic regression models will be constructed to identify independent predictors of high SYNTAX scores, adjusting for potential confounders.
This study is expected to contribute to the understanding of LGI as a simple, cost-effective, and accessible biomarker for predicting coronary artery disease complexity in ACS patients
- Conditions
- Acute Coronary Syndromes (ACS)
- Being tested
- leukoglycemic index calculation
- Keywords
- Acute coronary syndrome, Coronary artery disease, inflammation, risk stratification, SYNTAX score, leukoglycemic index
- Medical subject headings
- Acute Coronary Syndrome, Coronary Artery Disease, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
leukoglycemic index calculationOther
leukoglycemic index calculation
| Study group | Role | What they receive |
|---|---|---|
| SYNTAX score =<22 | Not described Receives: Other: leukoglycemic index calculation | |
| SYNTAX score >22 | Not described Receives: Other: leukoglycemic index calculation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Leukoglycemic Index (LGI)
The LGI is calculated as the product of blood glucose concentration (mg/dL) and leukocyte count (cells/mm³). This composite measure provides a single numerical value that reflects both metabolic status (via blood glucose) and hematological status (via white blood cell count). At baseline, LGI serves as an integrated indicator of participants' metabolic and immune activity. It is simple to compute and offers a practical way to capture two fundamental aspects of health in one measure. Higher values are considered worse outcomes because they reflect an increased metabolic and inflammatory burden
Measured: First day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2025
- Study start24 Sep 2025
- Primary completion21 Oct 2025
- Study completion21 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Acute Coronary Syndromes (ACS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 552 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kırıkkale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rukiye Gonen Ozdemir, Kırıkkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07276256
- Sponsor's protocol ID
- 2024.05.19
- Status last verified
- Dec 2025
- First submitted
- 28 Nov 2025
- Last updated
- 25 Feb 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association Between SYNTAX Score and Leukoglycemic Index In Patients Wiht Acute Coronary Syndrome
- ClinicalTrials.gov ID
- NCT07276256
- Acronym / sponsor ID
- 2024.05.19
- Conditions
- Acute Coronary Syndromes (ACS)
- Keywords
- Acute coronary syndrome, Coronary artery disease, inflammation, risk stratification, SYNTAX score, leukoglycemic index
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 552 participants (actual)
- Lead sponsor
- Kırıkkale UniversityUniversity, hospital or other
- Study start
- 24 Sep 2025 (actual)
- Primary completion
- 21 Oct 2025 (actual)
- Study completion
- 21 Oct 2025 (actual)
- First posted
- 11 Dec 2025 (actual)
- Results
- Posted 25 Feb 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at people who come to the hospital with acute coronary syndrome, a serious heart condition. When these patients first arrive, doctors take routine blood tests. The investigators use these test results to calculate a value called the leukoglycemic index (LGI), which combines white blood cell count and blood sugar level. The investigators also use a heart imaging score called the SYNTAX score to see how complex their coronary artery disease is.
Patients are divided into two groups based on their SYNTAX scores: one group with lower scores (22 or less), and one with higher scores (above 22). The investigators compare their health data to see if LGI is linked to the severity of their heart disease. The investigators also check if LGI can help predict how complex the disease is. Information like age, family history, and chronic illnesses is collected from patient records and medical interviews.
Detailed description
This observational study aims to evaluate the association between the SYNTAX score-a validated angiographic tool used to assess the complexity of coronary artery disease-and the leukoglycemic index (LGI), a composite biomarker calculated from white blood cell count and blood glucose level. The study population consists of patients diagnosed with acute coronary syndrome (ACS) who were admitted to the hospital and underwent coronary angiography as part of their clinical evaluation.
At the time of initial hospital admission, routine laboratory parameters were obtained, including complete blood count and fasting glucose levels. These values were used to calculate the LGI. Patients were stratified into two groups based on their SYNTAX scores: Group I (SYNTAX score ≤22) and Group II (SYNTAX score >22). Demographic characteristics, family history of cardiovascular disease, and chronic comorbidities (such as diabetes mellitus, hypertension, and hyperlipidemia) were extracted from patient medical records and clinical anamnesis.
The primary objective of the study is to determine whether LGI correlates with the angiographic severity of coronary artery disease as measured by the SYNTAX score. Secondary objectives include identifying independent predictors of coronary complexity and evaluating the potential role of LGI as a non-invasive biomarker in risk stratification.
Statistical analyses will be performed using SPSS software. Normality of data distribution will be assessed using the Shapiro-Wilk test. Depending on distribution characteristics, appropriate parametric (e.g., Student's t-test) or non-parametric (e.g., Mann-Whitney U test) methods will be applied for group comparisons. Pearson correlation analysis will be used to assess the relationship between LGI and SYNTAX score. Multivariate linear and logistic regression models will be constructed to identify independent predictors of high SYNTAX scores, adjusting for potential confounders.
This study is expected to contribute to the understanding of LGI as a simple, cost-effective, and accessible biomarker for predicting coronary artery disease complexity in ACS patients
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SYNTAX score =<22 | – | Other: leukoglycemic index calculation |
| SYNTAX score >22 | – | Other: leukoglycemic index calculation |
Who may qualify
- Ages
- 18 to 88 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with acute coronary syndrome
Key inclusion criteria (2 listed)
- Adult patients aged 18 years and older
- Patients who underwent coronary angiography due to acute coronary syndrome
Key exclusion criteria (4 listed)
- Patients with diabetes mellitus (Diagnosis based on current use of oral antidiabetic or insulin therapy and/or fasting glucose level ≥126 mg/dL and HbA1c ≥6.5%)
- Patients with atrial fibrillation, history of pacemaker implantation, asthma, pulmonary hypertension, pregnancy, anemia, malignancy, rheumatoid arthritis, or peripheral artery disease
- Obese individuals (defined as body mass index [BMI] >30 kg/m²)
- Patients whose medical records could not be accessed
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| leukoglycemic index calculationleukoglycemic index calculation | Other | SYNTAX score =<22, SYNTAX score >22 |
Primary outcome
Leukoglycemic Index (LGI)
Time frame: First day
The LGI is calculated as the product of blood glucose concentration (mg/dL) and leukocyte count (cells/mm³). This composite measure provides a single numerical value that reflects both metabolic status (via blood glucose) and hematological status (via white blood cell count). At baseline, LGI serves as an integrated indicator of participants' metabolic and immune activity. It is simple to compute and offers a practical way to capture two fundamental aspects of health in one measure. Higher values are considered worse outcomes because they reflect an increased metabolic and inflammatory burden
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Acute Coronary Syndromes (ACS)
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
RecruitingPhase 4
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
Not yet recruitingPhase 3
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)
Not yet recruitingObservational study
Prognostic Value of Functional-Nutritional Status in Older Adults With Acute Coronary Syndrome
Acute Coronary Syndromes (ACS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndromes (ACS), run by Kırıkkale University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 Feb 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Leukoglycemic Index (LGI) (time frame: First day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.